Acute and Chronic Leukemias

Expert faculty review and share their insights and perspectives on key findings in acute and chronic leukemias presented at the 2020 ASH Annual Meeting.

Share

Program Content

Activities

  • Expert Analysis
    Key Studies in Leukemias: Independent Conference Coverage of ASH 2020
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 12, 2021

    Expires: February 11, 2022

  • ClinicalThought
    Expert Selections From ASH 2020: Acute and Chronic Myeloid Leukemias
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 03, 2021

    Expires: March 02, 2022

  • Podcast
    Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias
    Conference Coverage
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2021

    Expires: February 25, 2022

Activities

QUAZAR AML-001
Phase III QUAZAR AML-001: Analyses of CC-486 (Oral Azacitidine) vs Placebo as Maintenance Therapy in AML After CR/CRi
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

Gilteritinib in ND AML
Phase I Study of Gilteritinib Combined With Induction/Consolidation Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia: Final Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

Magrolimab + Aza in AML
Phase Ib Efficacy, Safety of Anti-CD47 Antibody Magrolimab + Azacitidine in Untreated AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2020

Expires: December 06, 2021

Flotetuzumab in AML
Phase I/II Trial of Flotetuzumab as Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Hyper-CVAD + Blinatumomab in B-Cell ALL
Phase II Study of Hyper-CVAD + Blinatumomab in Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

OPTIC Interim Analysis
Randomized Phase II OPTIC Trial of 3 Starting Doses of Ponatinib in Patients With CP-CML: Analysis by Mutation Status and Line of Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Ponatinib After Sec-Gen TKI
Ponatinib After Progression on Second-Generation TKI Therapy in Chronic-Phase Chronic Myeloid Leukemia: Combined Analysis of PACE and OPTIC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Asciminib in <i>T315I</i> CML
Updated Analysis of Phase I Trial of Asciminib, a First-in-Class STAMP Inhibitor, in Patients With Previously Treated BCR-ABL1 T315I–Mutated CML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2020

Expires: December 15, 2021

QUAZAR AML-001: MRD
QUAZAR AML-001 Phase III Trial of Oral AZA (CC-486) vs Placebo as Maintenance Therapy in AML After First Remission: Analyses by MRD Status
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

ASCEMBL
ASCEMBL: Phase III Study of STAMP Inhibitor Asciminib vs Bosutinib for CML-CP Previously Treated With ≥ 2 TKIs
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Faculty

cover img faculity

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology